Claims
- 1. A method for determining whether a compound is capable of suppressing the ras functions comprising:
(a) contacting an effective amount of the compound with Ha-ras transformed cloned rat embryo fibroblast cells under conditions permitting the compound to suppress the ras functions in the cells; and (b) determining the expression of lysyl oxidase, the expression of lysyl oxidase indicating that the compound is capable of suppressing the ras functions.
- 2. A method for determining whether a compound is capable of suppressing the ras functions comprising:
(a) contacting an effective amount of the compound with Ha-ras transformed cloned rat embryo fibroblast cells under conditions permitting the compound to suppress the ras functions in the cells; and (b) determining the expression of TIMP-1, the expression of TIMP-1 indicating that the compound is capable of suppressing the ras functions.
- 3. A method for determining whether a compound is capable of suppressing the ras functions comprising:
(a) contacting an effective amount of the compound with Ha-ras transformed cloned rat embryo fibroblast cells under conditions permitting the compound to suppress the ras functions in the cells; and (b) determining the expression of 92-kDa gelatinase, the inhibition of the expression of 92-kDa gelatinase indicating that the compound is capable of suppressing the ras functions.
- 4. A method for determining whether a compound is capable of suppressing the ras functions comprising:
(a) contacting an effective amount of the compound with Ha-ras transformed cloned rat embryo fibroblast cells under conditions permitting the compound to suppress the ras functions in the cells; and (b) determining the expression of transin, the inhibition of the expression of transin indicating that the compound is capable of suppressing the ras functions.
- 5. A method of claim 1, 2, 3 or 4, where the compound was not previously known.
- 6. The compound determined to be capable of suppressing the ras functions by method of claim 5.
- 7. A pharmaceutical composition comprising the compound determined to be capable of suppressing the ras functions by method of claim 1, 2, 3, or 4 and a pharmaceutically acceptable carrier.
- 8. A method for generating transcriptional switched Ha-ras transformed cloned rat embryo fibroblast cells comprising:
(a) introducing a gene to the Ha-ras transformed cloned rat embryo fibroblast cells; and (b) determining the expression of lysyl oxidase in the introduced cells, the expression of lysyl oxidase indicating that the cells are transcriptional switched.
- 9. A method for generating transcriptional switched Ha-ras transformed cloned rat embryo fibroblast cells comprising:
(a) introducing a gene to the Ha-ras transformed cloned rat embryo fibroblast cells; and (b) determining the expression of TIMP-1 in the introduced cells, the expression of TIMP-1 indicating that the cells are transcriptional switched.
- 10. A method for generating transcriptional switched Ha-ras transformed cloned rat embryo fibroblast cells comprising:
(a) introducing a gene to the Ha-ras transformed cloned rat embryo fibroblast cells; and (b) determining expression of the 92-kDa gelatinase in the introduced cells, the inhibition of the expression of the 92-kDa gelatinase indicating that the cells are transcriptional switched.
- 11. A method for generating transcriptional switched Ha-ras transformed cloned rat embryo fibroblast cells comprising:
(a) introducing a gene to the Ha-ras transformed cloned rat embryo fibroblast cells; and (b) determining expression of the transin in the introduced cells, the inhibition of the expression of the transin indicating that the cells are transcriptional switched.
- 12. A method of claim 8, 9, 10, or 11, wherein the gene is a tumor suppressor gene.
- 13. A method of claim 12, wherein the tumor suppressor gene is Krev-1.
- 14. Cells generated by methods of claim 8, 9, 10, 11, 12 or 13.
- 15. A method to isolate genes which are associated with transcriptional switching of the Ha-ras transformed cloned rat embryo fibroblast cells comprising:
(a) selecting genes which are either expressed or suppressed in the transcriptional switched Ha-ras transformed cloned rat embryo fibroblast cells; and (b) isolating the selected gene.
- 16. A method of claim 15, wherein the genes are selected by subtractive hybridization.
- 17. A method of claim 15, wherein the genes are selected by differential display.
- 18. Genes isolated by the method of claim 15, 16 or 17.
- 19. Polypeptides encoded by the genes of claim 18.
- 20. Molecules capable of competitively inhibiting the functions of the polypeptides of claim 19.
- 21. Molecules capable of mimicking the functions of the polypeptides of claim 19.
Parent Case Info
[0001] This application claims priority of U.S. provisional application No. 60/007,543, filed Nov. 24, 1995, the content of which is incorporated into this application by reference.
Government Interests
[0002] The invention disclosed herein was made with Government support under NCI/NIH CA 35675 from the Department of Health and Human Service. Accordingly, the U.S. Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60007543 |
Nov 1995 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09812033 |
Mar 2001 |
US |
Child |
10395614 |
Mar 2003 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08749737 |
Nov 1996 |
US |
Child |
09812033 |
Mar 2001 |
US |